European Commission Approves Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for Cervical Cancer

Article

Patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 can receive treatment with pembrolizumab plus chemotherapy with or without bevacizumab following approval by the European Commission.

The European Commission has approved pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab (Avastin) for patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 and who have a combined positive score of 1 or greater, according to a press release from Merck.1

The approval was based on findings from the phase 3 KEYNOTE-826 trial (NCT03635567), which assessed pembrolizumab plus chemotherapy plus or minus bevacizumab vs chemotherapy.2 Patients had an improved overall survival (OS; HR, 0.64; 95% CI, 0.50-0.81; P = .0001), and progression-free survival (HR, 0.62; 95% CI, 0.50-0.77; P <.0001) compared with the placebo arm.

“With today’s approval, healthcare providers in the EU will be able to offer certain patients with advanced cervical cancer a long-awaited immunotherapy option that has shown significant improvement in [OS].” Nicoletta Colombo, MD, PhD, associate professor at the University of Milan-Bicocca, and director of the Gynecologic Oncology Program at the European Institute of Oncology in Milan, Italy, said in a press release

Pembrolizumab plus chemotherapy with or without bevacizumab has previously been approved by the FDA in October 2021 and was based on the results from the phase 3 KEYNOTE-826 trial.3

References

  1. European Commission approved Merck’s Keytruda (pembrolizumab) plus chemotherapy, with or without bevacizumab, for patients with persistant, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥ 1). News Release. Merck. April 29, 2022. Accessed May 2, 2022. https://bit.ly/3kxze1D
  2. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856-1867. doi:10.1056/NEJMoa2112435
  3. FDA approves Merck’s Keytruda (pembrolizumab) plus chemotherapy, with or without bevacizumab, as treatment for patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥ 1). News Release. Merck. October 13, 2021. Accessed May 2, 2022. https://bit.ly/3vXoS0u

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Related Content
UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

Tim Cortese
April 18th 2025
Article

Results from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin with chemotherapy in relapsed/refractory multiple myeloma.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Tim Cortese
April 15th 2025
Article

The addition of chemotherapy to radiotherapy did not show significant improvements in OS when compared with radiotherapy alone in patients with intermediate-risk cervical cancer.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC

Russ Conroy
April 2nd 2025
Article

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
April 2nd 2025
Article

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.